Eleutheroside E (Standard)

Eleutheroside E (Standard) is the analytical standard of Eleutheroside E. This product is intended for research and analytical applications. Eleutheroside E is an important component of Eleutheroside and has antioxidant, anti-fatigue, anti-inflammatory, antibacterial, immunomodulatory and cardioprotective effects. Eleutheroside E may inhibit the MAPK signaling pathway, thereby inhibiting H/R-induced NF-κB activation and oxidative stress, reducing metabolic reprogramming, and protecting myocardium from ischemia-reperfusion (I/R) injury. Eleutheroside E also counteracts the effects of high altitude hypobaric hypoxia (HAHI) by inhibiting inflammation and pyroptosis[1][2][3][4][5].

COC(C=C1[C@H]2[C@@](CO[C@@H]3C4=CC(OC)=C(O[C@@H]([C@@H]([C@@H](O)[C@@H]5O)O)O[C@@H]5CO)C(OC)=C4)([H])[C@]3([H])CO2)=C(C(OC)=C1)O[C@@H]([C@@H]([C@@H](O)[C@@H]6O)O)O[C@@H]6CO

[1]Chunyan He, et al. Eleutheroside E Ameliorates Arthritis Severity
 in Collagen-Induced Arthritis Mice Model
 by Suppressing Inflammatory Cytokine Release. Inflammation, Vol. 37, No. 5, October 2014 (# 2014)|[2]Jiyun Ahn, et al. Eleutheroside E, An Active Component of Eleutherococcus senticosus, Ameliorates Insulin Resistance in Type 2 Diabetic db/db Mice. Evid Based Complement Alternat Med. 2013; 2013: 934183.|[3]Wang S, et al. Eleutheroside E decreases oxidative stress and NF-κB activation and reprograms the metabolic response against hypoxia-reoxygenation injury in H9c2 cells. Int Immunopharmacol. 2020 Jul;84:106513.|[4]Ma B, et al. Simultaneous determination of Eleutheroside B and Eleutheroside E in rat plasma by high performance liquid chromatography-electrospray ionization mass spectrometry and its application in a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Feb 15;917-918:84-92.|[5]Jia N, et al. Eleutheroside E from pre-treatment of Acanthopanax senticosus (Rupr.etMaxim.) Harms ameliorates high-altitude-induced heart injury by regulating NLRP3 inflammasome-mediated pyroptosis via NLRP3/caspase-1 pathway. Int Immunopharmacol. 2023 Aug;121:110423.